An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway

PLoS Computational Biology

Volumn 10, Issue 3, 2014, Pages

  Lu, James ^a   Hübner, Katrin ^b   Nanjee, M Nazeem ^c   Brinton, Eliot A ^d   Mazer, Norman A ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF UTAH   (United States)

^d Utah Foundation for Biomedical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; CHOLESTEROL; METABOLISM; MODULATION; PHYSIOLOGY;

ATP BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CHOLESTERYL ESTER TRANSFER PROTEINS; DISEASE RISKS; HIGH DENSITY LIPOPROTEIN; IN-SILICO MODELS; PROTEIN INHIBITION; TRANSPORT RATE; UP-REGULATION;

LIPOPROTEINS;

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CALIBRATION; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL TRANSPORT; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; GENE MUTATION; INFORMATION RETRIEVAL; LIPOPROTEIN METABOLISM; LIPOPROTEIN METABOLISM AND KINETICS MODEL; LIPOPROTEIN SYNTHESIS; STRUCTURE ANALYSIS; UPREGULATION; VIRTUAL REALITY;

ALGORITHMS; ATP BINDING CASSETTE TRANSPORTER 1; BAYES THEOREM; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CALIBRATION; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS; MALE;

EID: 84897435471     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003509     Document Type: Article

References (93)

1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302: 1993-2000.
2. Larach DB, deGoma EM, Rader DJ, (2012) Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep 14: 684-691.
3. Hersberger M, von Eckardstein A, (2005) Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handb Exp Pharmacol 170: 537-561.
4. Rothblat GH, Phillips MC, (2010) High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21: 229-238.
5. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122.
6. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267.
7. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089-2099.
8. Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, et al. (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125: 1905-1919.
9. Rader DJ, Tall AR, (2012) The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 18: 1344-1346.
10. Heinecke JW, (2012) The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk? Nat Med 18: 1346-1347.
11. de Graaf AA, van Schalkwijk DB, (2011) Computational models for analyzing lipoprotein profiles. Clinical Lipidology 6: 25-33.
12. Lu J, Mazer NA, Hübner K, (2013) Mathematical models of lipoprotein metabolism and kinetics-current status and future perspectives. Clinical Lipidology 8: 595-604.
13. Potter LK, Sprecher DL, Walker MC, Tobin FL, (2009) Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro. J Lipid Res 50: 2222-2234.
14. van Schalkwijk DB, de Graaf AA, van Ommen B, van Bochove K, Rensen PC, et al. (2009) Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res 50: 2398-2411.
15. Knoblauch H, Schuster H, Luft FC, Reich J, (2000) A pathway model of lipid metabolism to predict the effect of genetic variability on lipid levels. J Mol Med 78: 507-515.
16. Hübner K, Schwager T, Winkler K, Reich JG, Holzhütter HG, (2008) Computational lipidology: predicting lipoprotein density profiles in human blood plasma. PLoS Comput Biol 4: e1000079.
17. van de Pas NC, Woutersen RA, van Ommen B, Rietjens IM, de Graaf AA, (2012) A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans. J Lipid Res 53: 2734-2746.
18. Mc Auley MT, Wilkinson DJ, Jones JJ, Kirkwood TB, (2012) A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst Biol 6: 130.
19. Tiemann CA, Vanlier J, Oosterveer MH, Groen AK, Hilbers PA, et al. (2013) Parameter trajectory analysis to identify treatment effects of pharmacological interventions. PLoS Comput Biol 9: e1003166.
20. Ouguerram K, Krempf M, Maugeais C, Maugere P, Darmaun D, et al. (2002) A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans. Metab Clin Exp 51: 5-11.
21. Schwartz CC, VandenBroek JM, Cooper PS, (2004) Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 45: 1594-1607.
22. Chetiveaux M, Ouguerram K, Zair Y, Maugere P, Falconi I, et al. (2004) New model for kinetic studies of HDL metabolism in humans. Eur J Clin Invest 34: 262-267.
23. Rye KA, Clay MA, Barter PJ, (1999) Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145: 227-238.
24. Adiels M, Packard C, Caslake MJ, Stewart P, Soro A, et al. (2005) A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 46: 58-67.
25. Mazer NA, Giulianini F, Paynter NP, Jordan P, Mora S, (2013) A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem 59: 949-958.
26. Scanu AM, Edelstein C, (2008) HDL: bridging past and present with a look at the future. FASEB J 22: 4044-4054.
27. Kontush A, Chapman MJ, (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inammation, and atherosclerosis. Pharmacol Rev 58: 342-374.
28. Moestrup SK, Kozyraki R, (2000) Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 11: 133-140.
29. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, et al. (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421: 75-79.
30. Chapman MJ, Le Goff W, Guerin M, Kontush A, (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31: 149-164.
31. Aster R, Borchers B, Thurber C (2005) Parameter Estimation and Inverse Problems. Academic Press.
32. Klinke DJ, (2009) An empirical Bayesian approach for model-based inference of cellular signaling networks. BMC Bioinformatics 10: 371.
33. Eydgahi H, Chen WW, Muhlich JL, Vitkup D, Tsitsiklis JN, et al. (2013) Properties of cell death models calibrated and compared using Bayesian approaches. Mol Syst Biol 9: 644.
34. Gisleskog PO, Karlsson MO, Beal SL, (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29: 473-505.
35. Jonsson F, Jonsson EN, Bois FY, Marshall S, (2007) The application of a Bayesian approach to the analysis of a complex, mechanistically based model. J Biopharm Stat 17: 65-92.
36. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, et al. (2011) Genetic variant of the scavenger receptor BI in humans. N Engl J Med 364: 136-145.
37. Vaziri ND, Navab M, Fogelman AM, (2010) HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6: 287-296.
38. Fabre AC, Vantourout P, Champagne E, Terce F, Rolland C, et al. (2006) Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 63: 2829-2837.
39. Ritsch A, Drexel H, Amann FW, Pfeifhofer C, Patsch JR, (1997) Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol 17: 3433-3441.
40. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, et al. (1995) Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 96: 1573-1581.
41. Teh EM, Dolphin PJ, Breckenridge WC, Tan MH, (1998) Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. J Lipid Res 39: 442-456.
42. Carlson LA, Holmquist L, (1985) Evidence for the presence in human plasma of lecithin: cholesterol acyltransferase activity (beta-LCAT) specifically esterifying free cholesterol of combined pre-betaand beta-lipoproteins. Studies of fish eye disease patients and control subjects. Acta Med Scand 218: 197-205.
43. Brinton EA, Eisenberg S, Breslow JL, (1994) Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14: 707-720.
44. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, et al. (1982) Human apolipoprotein A-I and A-II metabolism. J Lipid Res 23: 850-862.
45. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, et al. (1993) Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 92: 1650-1658.
46. Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, et al. (2001) Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 156: 217-225.
47. Santos RD, Schaefer EJ, Asztalos BF, Polisecki E, Wang J, et al. (2008) Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res 49: 349-357.
48. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, et al. (1993) Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 34: 2207-2215.
49. Moss R, Grosse T, Marchant I, Lassau N, Guey_er F, et al. (2012) Virtual patients and sensitivity analysis of the Guyton model of blood pressure regulation: towards individualized models of wholebody physiology. PLoS Comput Biol 8: e1002571.
50. Schwartz GG, Olsson AG, Barter PJ, (2013) Dalcetrapib in patients with an acute coronary syndrome. N Engl J Med 368: 869-870.
51. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, et al. (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24: 490-497.
52. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, et al. (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363: 2406-2415.
53. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380: 572-580.
54. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, et al. (2012) High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 60: 508-516.
55. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, et al. (2010) High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 56: 1128-1137.
56. Kane JP, Malloy MJ, (2012) Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol 23: 367-371.
57. Kaess BM, Tomaszewski M, Braund PS, Stark K, Rafelt S, et al. (2011) Large-scale candidate gene analysis of HDL particle features. PLoS ONE 6: e14529.
58. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, et al. (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40: 781-796.
59. Patel DC, Albrecht C, Pavitt D, Paul V, Pourreyron C, et al. (2011) Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS ONE 6: e22142.
60. Paul V, Meyer HH, Leidl K, Soumian S, Albrecht C, (2008) A novel enzyme immunoassay specific for ABCA1 protein quantification in human tissues and cells. J Lipid Res 49: 2259-2267.
61. Nanjee MN, Brinton EA, (2000) Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography. Clin Chem 46: 207-223.
62. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, et al. (2005) Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25: 2185-2191.
63. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, et al. (2003) Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23: 847-852.
64. Hirayama S, Miida T, Miyazaki O, Aizawa Y, (2007) Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 30: 1289-1291.
65. de Vries R, Perton FG, van Tol A, Dullaart RP, (2012) Carotid intima media thickness is related positively to plasma pre-high density lipoproteins in non-diabetic subjects. Clin Chim Acta 413: 473-477.
66. Guey LT, Pullinger CR, Ishida BY, O'Connor PM, Zellner C, et al. (2011) Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol 108: 360-366.
67. Shah A, Rader DJ, Millar JS, (2010) The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 210: 35-40.
68. Apostoli AJ, Nicol CJ, (2012) PPAR Medicines and Human Disease: The ABCs of It All. PPAR Res 2012: 504918.
69. Rodrigueza WV, Williams KJ, Rothblat GH, Phillips MC, (1997) Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler Thromb Vasc Biol 17: 383-393.
70. Tchoua U, Gillard BK, Pownall HJ, (2010) HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis 209: 430-435.
71. Shen BW, Scanu AM, Kezdy FJ, (1977) Structure of human serum lipoproteins inferred from compositional analysis. Proc Natl Acad Sci USA 74: 837-841.
72. Li X, Stolinski M, Umpleby AM, (2012) Development of a method to measure pre-β HDL and α-HDL apoA-I enrichment for stable isotopic studies of HDL kinetics. Lipids 47: 1011-1018.
73. Braschi S, Neville TA, Maugeais C, Ramsamy TA, Seymour R, et al. (2000) Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry 39: 5441-5449.
74. Bojanovski D, Gregg RE, Zech LA, Meng MS, Bishop C, et al. (1987) In vivo metabolism of proapolipoprotein A-I in Tangier disease. J Clin Invest 80: 1742-1747.
75. Schaefer EJ, Anderson DW, Zech LA, Lindgren FT, Bronzert TB, et al. (1981) Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J Lipid Res 22: 217-228.
76. Cavigiolio G, Geier EG, Shao B, Heinecke JW, Oda MN, (2010) Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem 285: 18847-18857.
77. Cheung MC, Wolf AC, Knopp RH, Foster DM, (1992) Protein transfer between A-I-containing lipoprotein subpopulations: evidence of non-transferable A-I in particles with A-II. Biochim Biophys Acta 1165: 68-77.
78. Lund-Katz S, Nguyen D, Dhanasekaran P, Kono M, Nickel M, et al. (2010) Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles. J Lipid Res 51: 606-617.
79. Castro GR, Fielding CJ, (1988) Early incorporation of cell-derived cholesterol into pre-betamigrating high-density lipoprotein. Biochemistry 27: 25-29.
80. Sorci-Thomas MG, Owen JS, Fulp B, Bhat S, Zhu X, et al. (2012) Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res 53: 1890-1909.
81. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, et al. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323: 1234-1238.
82. Yamashita S, Hui DY, Wetterau JR, Sprecher DL, Harmony JA, et al. (1991) Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. Metab Clin Exp 40: 756-763.
83. Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, et al. (2004) Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 45: 448-455.
84. Press WH, Teukolsky SA, Vetterling WT, Flannery BP (1992) Numerical recipes in C (2nd ed.): the art of scientific computing. Cambridge, UK: Cambridge University Press.
85. Martins JRRA, Sturdza P, Alonso JJ, (2003) The complex-step derivative approximation. ACM Trans Math Software 29: 245-262.
86. Apgar JF, Witmer DK, White FM, Tidor B, (2010) Sloppy models, parameter uncertainty, and the role of experimental design. Mol Biosyst 6: 1890-1900.
87. Wei XN, Han BC, Zhang JX, Liu XH, Tan CY, et al. (2011) An integrated mathematical model of thrombin-, histamine-and VEGF-mediated signalling in endothelial permeability. BMC Syst Biol 5: 112.
88. Velez-Carrasco W, Lichtenstein AH, Li Z, Dolnikowski GG, Lamon-Fava S, et al. (2000) Apolipoprotein A-I and A-II kinetic parameters as assessed by endogenous labeling with [(2)H(3)]leucine in middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol 20: 801-806.
89. Schaefer EJ, Santos RD, Asztalos BF, (2010) Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 21: 289-297.
90. Barter PJ, (2002) Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler Suppl 3: 39-47.
91. Miyazaki O, Fukamachi I, Mori A, Hashimoto H, Kawashiri MA, et al. (2009) Formation of prebeta1-HDL during lipolysis of triglyceride-rich lipoprotein. Biochem Biophys Res Commun 379: 55-59.
92. Liang HQ, Rye KA, Barter PJ, (1994) Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res 35: 1187-1199.
93. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, et al. (2001) The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 276: 26898-26905.